Výsledky vyhledávání - "Mary L. Owens"

Mortality Associated with Implantation and Management of Intrathecal Opioid Drug Infusion Systems to Treat Noncancer Pain

Autor: Lisa Stearns, Michael S. Turner, David M. Schultz, F. Michael Ferrante, Steven K. Broste, Robert J. Coffey, Michel Y. Dubois, Mary L. Owens

Publikováno v: Anesthesiology. 111:881-891

Background In 2006, the authors observed a cluster of three deaths, which circumstances suggested were opioid-related, within 1 day after placement of intrathecal opioid pumps for noncancer pain. Further investigation suggested that mortality among s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98aedd3d0417595ad82169516bcfb308
https://doi.org/10.1097/aln.0b013e3181b64ab8

Zobrazit plný text záznamu

Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks

Autor: Kurt Gebauer, Mary L. Owens, Christopher J Quirk, Patti Stampone

Publikováno v: Australasian Journal of Dermatology. 47:258-265

SUMMARY Imiquimod 5% cream is approved in the USA, Europe and Australia to treat superficial basal cell carcinoma, using a regimen of once daily, 5 times per week for 6 weeks. Vehicle-controlled, phase III clinical trials show that imiquimod is safe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c2947c31aed44284e244d53046999de0
https://doi.org/10.1111/j.1440-0960.2006.00313.x

Zobrazit plný text záznamu

Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation

Autor: Margo Liberda, Michael L. Smith, Mary L. Owens, Kays Kaidbey

Publikováno v: Toxicology. 178:175-182

Background: Imiquimod 5% topical cream is an immune response modifier that induces interferon alpha and interleukin-12, and exhibits antiviral and tumor-inhibiting properties. It is currently available for treatment of genital and perianal warts. Thr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ca605d7aacdb05f99e7cb1f9e5dd58d
https://doi.org/10.1016/s0300-483x(02)00320-7

Zobrazit plný text záznamu

Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial

Autor: Robin Marks, Stephen Shumack, Terry L. Fox, Mark Amies, Kurt Gebauer, James Bryden, Mary L. Owens

Publikováno v: Journal of the American Academy of Dermatology. 44:807-813

Background: Superficial basal cell carcinoma (sBCC) is an increasingly common tumor in fair-skinned populations throughout the world. Imiquimod, an immune response modifier that induces cytokines including interferons, has been shown in preliminary s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9987c267a6435c10c153de759b7682b4
https://doi.org/10.1067/mjd.2001.113689

Zobrazit plný text záznamu

Treatment of External Genital Warts in Men Using 5% Imiquimod Cream Applied Three Times a Week, Once Daily, Twice Daily, or Three Times a Day

Autor: Darron R. Brown, John M. Douglas, Mary L. Owens, M.H. Smith, Kenneth H. Fife, Alex Ferenczy

Publikováno v: Sex Transm Dis. 28:226-231

Background Medical therapy for genital warts remains suboptimal. The topical interferon and cytokine inducer, imiquimod, has been proved effective for the treatment of external genital and perianal warts, but there is a substantial difference in the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89040a28aab7911835fa1ba4778b3cd0
https://doi.org/10.1097/00007435-200104000-00007

Zobrazit plný text záznamu

A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients

Autor: Robert V. Swann, Jonathon N. Weber, Marcus A. Conant, Alvin E. Friedman-Kien, Andrew T. Nayagam, Richard Gilson, Diane C. Pietig, Michael H. Smith, Jerome L. Shupack, Mary L. Owens

Publikováno v: AIDS. 13:2397-2404

Objective: To assess the safety of imiquimod, an immune response modifier, in the topical treatment of external anogenital warts in HIV-infected patients.Setting: Clinical sites in the United Kingdom (eight) and the United States (five).Design: A pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aa26a39012e6d458c96123ad54ac0995
https://doi.org/10.1097/00002030-199912030-00011

Zobrazit plný text záznamu

Treatment of genital warts with an immune-response modifier (imiquimod)

Autor: Andrina J. Hougham, Terry L. Fox, Karl R. Beutner, Mary L. Owens, Spotswood L. Spruance, John M. Douglas

Publikováno v: Journal of the American Academy of Dermatology. 38:230-239

Genital warts are a common sexually transmitted disease caused by human papillomavirus. Imiquimod is a novel immune-response modifier capable of inducing a variety of cytokines, including interferon alfa, tumor necrosis factor-alpha, as well as inter

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a559b4b1e93261be1b5d3c9d3c2d412
https://doi.org/10.1016/s0190-9622(98)70243-9

Zobrazit plný text záznamu

Medical practice perspective: identification and mitigation of risk factors for mortality associated with intrathecal opioids for non-cancer pain

Autor: Lisa Stearns, Michael S. Turner, Mary L. Owens, Michel Y. Dubois, Steven K. Broste, F. Michael Ferrante, Robert J. Coffey, David M. Schultz

Publikováno v: Pain medicine (Malden, Mass.). 11(7)

Objective. The authors recently determined that early and longer term mortality after initiation or reinitiation of intrathecal opioid therapy is higher than previously appreciated: 0.088% within 3 days, 0.39% at 1 month, and 3.89% at 1 year. These r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab50477b46b69e91803b1150efda8498
https://pubmed.ncbi.nlm.nih.gov/20642727

Zobrazit plný text záznamu

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies

Autor: Patti Stampone, John K. Geisse, Loren E. Golitz, Jane S. Lindholm, Mary L. Owens, Ivor Caro

Publikováno v: Journal of the American Academy of Dermatology. 50(5)

Background Imiquimod is an immune response modifier that is a Toll-like receptor 7 agonist that induces interferon and other cytokines through the innate immune system and stimulates cell-mediated immunity through T cells. Imiquimod has been shown to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c91e6a14c6e6d4b96aa56ffedd564b0b
https://pubmed.ncbi.nlm.nih.gov/15097956

Zobrazit plný text záznamu

Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms

Autor: Sarala Kurup, Mary L. Owens, Lester I. Harrison, Robert J. Greene, Scott McKane, Shari L. Skinner, Thomas C. Marbury

Publikováno v: Archives of Dermatological Research. 296

The safety and efficacy of imiquimod 5% cream is being evaluated for the treatment of dysplastic lesions of the epidermis (actinic keratoses, AK). The objective of this clinical study was to describe the pharmacokinetics and safety of topical imiquim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbd70299b96f0768f38de1265334e20d
https://doi.org/10.1007/s00403-004-0465-4

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání